Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5198MR)

This product GTTS-WQ5198MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5198MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5574MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ5732MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ3665MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ13738MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ14191MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ9416MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ2547MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ11093MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCS-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW